NYSE:AGN - Allergan Stock Price, Forecast & News

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, January 24th. Shareholders of record on Friday, February 14th will be paid a dividend of $0.74 per share on Friday, March 13th. This represents a $2.96 dividend on an annualized basis and a yield of 1.49%. The ex-dividend date of this dividend is Thursday, February 13th. View Allergan's Dividend History.

Allergan declared that its board has authorized a stock repurchase plan on Tuesday, January 29th 2019, which permits the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 4.1% of its shares through open market purchases. Shares buyback plans are often an indication that the company's board believes its shares are undervalued.

Allergan plc (NYSE:AGN) issued its quarterly earnings results on Monday, February, 10th. The company reported $5.22 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $4.57 by $0.65. The firm earned $4.35 billion during the quarter, compared to analyst estimates of $4.09 billion. The firm's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the company earned $4.29 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Allergan.

19 equities research analysts have issued 1 year price targets for Allergan's shares. Their forecasts range from $144.95 to $203.00. On average, they expect Allergan's share price to reach $178.72 in the next twelve months. This suggests that the stock has a possible downside of 9.9%. View Analyst Price Targets for Allergan.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 16 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

Media headlines about AGN stock have trended neutral this week, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allergan earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Allergan.

Allergan saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 15,400,000 shares, an increase of 5.6% from the January 15th total of 14,580,000 shares. Based on an average trading volume of 2,360,000 shares, the days-to-cover ratio is presently 6.5 days. Approximately 4.7% of the company's shares are sold short. View Allergan's Current Options Chain.

Some companies that are related to Allergan include AbbVie (ABBV), The Medicines (MDCO), Assembly Biosciences (ASMB), Ampio Pharmaceuticals (AMPE), Melinta Therapeutics (MLNT), Acura Pharmaceuticals (ACUR), Akorn (AKRX), BioDelivery Sciences International (BDSI), Bristol-Myers Squibb (BMY), Corcept Therapeutics (CORT), Cumberland Pharmaceuticals (CPIX), Eli Lilly And Co (LLY), Endo International (ENDP), Horizon Therapeutics (HZNP) and Jazz Pharmaceuticals (JAZZ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Allergan's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (4.39%), Franklin Resources Inc. (2.24%), Longview Partners Guernsey LTD (2.10%), Renaissance Technologies LLC (1.53%), Bank of New York Mellon Corp (0.77%) and TIG Advisors LLC (0.68%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Assenagon Asset Management S.A., Fred Alger Management LLC, MUFG Securities EMEA plc, State Street Corp, FMR LLC, Fir Tree Capital Management LP and Commerzbank Aktiengesellschaft FI. View Insider Buying and Selling for Allergan.

AGN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Segantii Capital Management Ltd, Bank of Montreal Can, Beryl Capital Management LLC, Laurion Capital Management LP, FIL Ltd and Vivaldi Asset Management LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $198.32.